Welcome to our dedicated page for Perrigo Co Plc news (Ticker: PRGO), a resource for investors and traders seeking the latest updates and insights on Perrigo Co Plc stock.
Perrigo Company plc (NYSE: PRGO) is a pure-play self-care and consumer health company whose news flow is closely tied to its over-the-counter (OTC) product portfolio, category performance and strategic initiatives. The company regularly issues updates on its Consumer Self-Care Americas and Consumer Self-Care International segments, highlighting trends in categories such as Upper Respiratory, Pain & Sleep Aids, Digestive Health, Nutrition, Vitamins, Minerals and Supplements, Women’s Health, Skin Care, Oral Care and Healthy Lifestyle.
On this page, readers can follow Perrigo’s earnings announcements, where the company discusses net sales, organic growth, segment performance and the impact of divestitures and exited products. These releases often reference store brand market share gains in OTC categories, performance of key brands and progress under its Three-S plan (Stabilize, Streamline, Strengthen). Updates on Project Energize, the global investment and efficiency program designed to support the One Perrigo growth strategy, are also a recurring theme in recent communications.
Perrigo’s news also covers portfolio actions and strategic reviews. The company has disclosed an agreement to sell its Dermacosmetics branded business in certain European markets and has announced strategic reviews of its Oral Care and infant formula businesses. In addition, readers will find announcements related to dividends, participation in investor conferences and brand-level initiatives, such as collaborations involving Opill®, which Perrigo describes as the first daily birth control pill available without a prescription in the United States.
Investors, analysts and consumers can use this news feed to monitor how Perrigo is positioning its OTC and self-care portfolio, how its store brand and branded businesses are performing across regions and categories, and how management is adjusting the company’s structure and investments in response to market conditions.
Perrigo Company plc (NYSE: PRGO) announced the launch of its store brand equivalent of Voltaren Arthritis Pain, now available nationwide in the U.S. This topical gel, containing diclofenac sodium 1%, is the first store brand ANDA approved by the FDA for OTC use. Previously, generic prescription sales of Voltaren exceeded $250 million annually. The launch highlights Perrigo's OTC self-care platform, aimed at providing high-quality alternatives in self-care categories.
Perrigo Company (NYSE; TASE: PRGO) announced its participation in the Barclay's Global Consumer Staples Conference on September 9, 2020, with CEO Murray S. Kessler and CFO Ray Silcock hosting virtual one-on-one meetings.
Additionally, Kessler is set to present at the 18th Annual Morgan Stanley Global Healthcare Conference on September 17, 2020, at 8:45 am EST. The presentation will be accessible via a webcast on Perrigo's investor relations site.
Perrigo Company plc (NYSE: PRGO) has announced the acquisition of three OTC skincare and hair loss treatment brands—Emolium®, Iwostin®, and Loxon®—from Sanofi for approximately €21 million ($23 million). This strategic move aims to enhance Perrigo's self-care portfolio and strengthen its presence in the Eastern European market. The transaction, expected to close in Q4 2020, aligns with Perrigo's growth strategy focused on margin enhancement and market expansion. CEO Murray S. Kessler emphasized this acquisition will deliver shareholder value and bolster their product offerings.
Perrigo Company plc (PRGO) reported a strong performance in Q2 2020, with consolidated net sales of $1.2 billion, up 6.1% year-over-year. Adjusted diluted EPS rose 19.8% to $1.03. The company reaffirmed its fiscal 2020 outlook, projecting net sales growth of 6% to 7% and adjusted EPS between $3.95 and $4.15, despite challenges from COVID-19 costs. Consumer Self-Care Americas net sales increased 7.8% to $628 million, driven by e-commerce growth and strong demand for essential products.
Perrigo Company plc (NYSE; TASE: PRGO) has declared a quarterly dividend of $0.225 per share, with payment scheduled for September 15, 2020. Shareholders on record as of August 28, 2020 will receive this dividend.
The company aims to enhance individual well-being by providing Quality, Affordable Self-Care Products that consumers trust. This announcement reflects Perrigo's commitment to returning value to its shareholders.
Perrigo Company plc (NYSE; TASE: PRGO) will announce its second quarter financial results on August 5, 2020, with a conference call scheduled for 9:00 a.m. (EDT). Interested investors can access the call via webcast on Perrigo's investor relations website or by phone. A replay will be available from 12:00 p.m. (EDT) on the same day until midnight on August 12, 2020. The company focuses on providing affordable self-care products, enhancing the well-being of consumers, and is dedicated to transparency regarding future financial performance and associated risks.
Perrigo Company plc (NYSE: PRGO) has successfully closed a public offering of $750 million in 3.150% Senior Notes due 2030. The offering aims to collect approximately $737.1 million in net proceeds after expenses. Perrigo plans to utilize these proceeds primarily to redeem existing 3.500% Senior Notes due in 2021 and for other corporate purposes. The offering was managed by BofA Securities, J.P. Morgan, and Wells Fargo Securities.
Perrigo Company plc has finalized an agreement to sell its U.K.-based Rosemont Pharmaceuticals for £156 million, approximately $195 million, to a private equity firm. This deal marks a key step in Perrigo's strategy to transition to a consumer-focused self-care company. In 2019, Rosemont generated net sales of $53 million and contributed $0.12 to adjusted diluted EPS. CEO Murray S. Kessler emphasized the successful divestiture at an attractive tenfold adjusted operating income multiple, demonstrating commitment to shareholder value.
Perrigo Company plc (NYSE; TASE: PRGO) announced on June 17, 2020, a strategic investment in Kazmira LLC to enter the rapidly expanding CBD market. The deal includes a minority equity stake of approximately 20% for $50 million, aimed at producing THC-free CBD through a two-phase partnership. The first phase will enhance Kazmira's facilities to meet high-quality standards, while the second phase will launch CBD products in global markets. This collaboration aligns with Perrigo's vision to provide trusted self-care products and is expected to drive long-term growth for shareholders.
Perrigo Company plc announced a public offering of $750 million in 3.150% Senior Notes due 2030, priced at 99.170% of the principal amount. These notes will be fully guaranteed by Perrigo and are intended to fund the redemption of existing 3.500% Senior Notes due in 2021. The offering is expected to close on June 19, 2020, subject to customary conditions. This move aims to optimize financial costs by replacing higher interest debt with lower interest notes, thereby enhancing Perrigo's financial flexibility.
FAQ
What is the current stock price of Perrigo Co Plc (PRGO)?
What is the market cap of Perrigo Co Plc (PRGO)?
